Zoledronic acid promotes dental implant osseointegration in osteoporosis / 中国组织工程研究

ABSTRACT

BACKGROUND: Zoledronic acid can effectively enhance dental implant osseointegration, but it can also impair soft tissue and blood supply around the implant, eventually leading to bisphosphonate-associated osteonecrosis of the jaw. Therefore, it is a problem highly valued in implant restorations. OBJECTIVE: To review the application of zoledronic acid in the dental implantation after osteoporosis. METHODS: The first author searched PubMed and CNKI using computer for relevant articles concerning the potential mechanism by which zoledronic acid promotes dental implant osseointegration as well as its application in vitro and in vivo. The key words were "bisphosphonate, zoledronic acid, implant, osseointegration" in English and Chinese, respectively. RESULTS AND CONCLUSION: Zoledronic acid has been demonstrated to inhibit bone resorption and promote bone formation via local or systemic use, single or combined use with other drugs. However, the inhibition of osteoclasts by zoledronic acid is associated with the dose and action time of zoledronic acid. Thus, further investigation on the specific mechanisms of zoledronic acid at different dose and with different action time are warranted. We should further elucidate the risk factors and determinants of osteonecrosis of the jaw through clinical studies, and then find effective approaches to reduce the risk of jaw osteonecrosis and to maximize the positive effect of zoledronic acid in the dental implantation.